Athens, Greece - 15 April 2016: Patients have poor knowledge of warfarin which may increase their risk of serious side effects, according to research presented today at EuroHeartCare 2016 by Dr Kjersti Oterhals, a nurse researcher at Haukeland University Hospital in Bergen, Norway.1
Culture
April 15, 2016, Barcelona, Spain: Studies presented today at The International Liver Congress™ 2016 in Barcelona, Spain, demonstrate that tenofovir alafenamide (TAF) improves patient safety while maintaining efficacy in patients with chronic Hepatitis B virus (HBV) infection compared to tenofovir disoproxil fumarate (Viread, TDF).
The studies demonstrate that regardless of Hepatitis B e antigen status (HBeAg*), 25mg of TAF once-daily was as effective as, and safer than, 300mg of TDF once-daily, with fewer negative changes in bone and kidney parameters.
April 15, 2016, Barcelona, Spain: Data from a Phase 2 clinical trial show that an investigational injectable treatment known as RG-101 in combination with a four week course of oral direct-acting antiviral (DAA) treatment was well tolerated and resulted in high virologic response rates post-treatment among Hepatitis C (HCV) infected patients with genotypes 1 and 4, who had not been treated previously.
April 15, 2016, Barcelona, Spain: A new algorithm designed to help physician decision-making in End-Stage Liver Disease (ESLD), was able to accurately predict death in 96% of patients with ESLD.
The algorithm, presented at The International Liver CongressTM in Barcelona, Spain, is based on a combination of pre-morbid liver function and Acute-on-Chronic Liver Failure (ACLF) grade, and allows physicians to help determine patients who were likely to benefit from intensive care unit (ICU) treatment compared with those who would not.
April 15, 2016, Barcelona, Spain: A new study, presented today at The International Liver Congress™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of Hepatitis B (HBV) prolongs overall survival and reduces the risk of the most common form of liver cancer (Hepatocellular Carcinoma, HCC) and scarring of the liver (cirrhosis).
The study showed that the risks of developing HCC and liver cirrhosis were significantly lowered among those who received nucleos(t)ide analogue treatment.
Athens, Greece - 15 April 2016: Greek dancing improves the jumping ability of elderly patients with heart failure, according to research published today in the European Journal of Cardiovascular Nursing.1 Patients randomised to Greek dancing jumped higher and faster than their sedentary counterparts. Those who danced had stronger legs and could walk further.
In the first study of its kind, Cornell sociologists have found that people who have a medical emergency in a public place can't necessarily rely on the kindness of strangers. Only 2.5 percent of people, or 1 in 39, got help from strangers before emergency medical personnel arrived, in research published April 14 in the American Journal of Public Health.
April 14, 2016 - Why are black older adults at higher risk of repeat hospital admission after a heart attack? Treatment at hospitals with higher rates of missed nursing care may be a contributing factor, reports a study in the May issue of Medical Care. The journal is published by Wolters Kluwer.
COLUMBUS, Ohio - New clinical-trial findings show that patients with a low-grade form of brain cancer who are treated with radiation plus a combination of chemotherapy drugs have better survival than patients treated with radiation alone.
Water filters of the future may be made from billions of tiny, graphene-based nanoscrolls. Each scroll, made by rolling up a single, atom-thick layer of graphene, could be tailored to trap specific molecules and pollutants in its tightly wound folds. Billions of these scrolls, stacked layer by layer, may produce a lightweight, durable, and highly selective water purification membrane.
CINCINNATI--Patients who get blood quickly after severe injuries are less likely to die, according to researchers from the University of Cincinnati (UC) Department of Emergency Medicine.
The research was published in the April 2016 issue of the Journal of Trauma and Acute Care Surgery.
"More than 180,000 people die from trauma every year," says Elizabeth Powell, MD, assistant professor of emergency medicine in the UC Department of Medicine and lead author on the study. "Bleeding is the major cause of preventable death after trauma."
GENEVA, Switzerland, 14 April 2016 - Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in patients with malignant pleural mesothelioma (MPM), according to the results of a phase Ib trial presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1
It is believed that the circular economy will radically transform the entire business sector in the next few years. Climate change will make our living conditions more challenging, and mankind will need to develop new ways to both conserve and produce resources such as water, food, energy and consumables. VTT asked schoolchildren to draw sketches of a fictional futuristic spaceship aboard which all waste and by-products of life need to be minimised and reused as efficiently as possible.
Can large group meditation lower the crime rate? The most recent in a series of studies spanning decades suggests again that a sufficiently large group practicing an advanced program of Transcendental Meditation, the TM-Sidhi program, is associated with decreased social violence.
For the period 2007-2010, when there was a sufficiently large group, statistical analysis found a significant decrease in both the national homicide rate and urban violent crime rate compared to trends during the baseline period of 2002-2006.
GENEVA, Switzerland, 14 April 2016 - The third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) osimertinib is effective in the first-line treatment of EGFR mutated non-small-cell lung cancer (NSCLC), according to a late-breaking abstract presented at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 A second late-breaking abstract confirms the drug's effectiveness in patients with the T790M mutation.